GLP-3 Retatrutide
Price range: $ 59.00 through $ 235.00
All products are for laboratory research purposes only. Not for human consumption, medical, or veterinary use. Novara Peptides does not condone or support the use of peptides outside of controlled scientific research. By purchasing, you acknowledge that you are a qualified researcher or institution. You must be 21 or older.
GLP-3R (LY-3437943) – Triple-Agonist Research Compound
GLP-3R is a lab-made peptide that activates GLP-1, GIP, and glucagon receptors. Therefore, researchers study it for its effects on metabolic pathways. Moreover, studies show strong impacts on weight control, blood sugar balance, and metabolic health. In addition, its triple-action design works more broadly than single-pathway compounds. As a result, scientists see GLP-3R as a key candidate in obesity and diabetes research. Finally, this compound is intended only for laboratory studies and not for human use.
Why Researchers Choose GLP-3R
Multi-Receptor Action — Works on GLP-1, GIP, and glucagon receptors to target many pathways [Wikipedia; PeptideFiles; Synapse].
Strong Metabolic Results — Early trials showed large weight drops and better metabolic markers [NEJM; MDPI].
Clear Dose Response — Higher doses in studies led to stronger results [MDPI; PeptideFiles].
Better Tolerance Over Time — Initially, digestive side effects may appear; however, they often improve when the dose is increased more slowly [MDPI; NEJM].
Wide Research Use — Studied for obesity, type 2 diabetes, heart health, and liver disease [MDPI; Policy Lab].
Important Note
For laboratory and scientific research only. Not for human use or therapy.Retatrutide
| Compound Name | GLP-3R (Triple-Agonist Peptide) |
| Form | Lyophilized peptide powder |
| Intended Research Use | Metabolism, energy expenditure, glucose & body composition research |
| Storage Conditions | −20 °C dry; 2–8 °C after reconstitution |
Weight Loss & Obesity
In phase 2 trials, GLP-3R induced weight reductions of ~17.5% by 24 weeks, and up to ~24.2% at 48 weeks at higher doses, compared to placebo. New England Journal of Medicine
Glucose Control & Metabolic Markers
Participants in clinical trials exhibited improvements in HbA1c and fasting glucose, with dose-dependent effects on insulin sensitivity. MDPI
Cardiovascular & Liver Outcomes
Early data show favorable shifts in lipid profiles, reductions in liver fat, and improvements in markers of cardiovascular risk. MDPI
Clinical Trial Status
GLP-3R is in late-phase trials (Phase 3) for obesity, type-2 diabetes, and associated metabolic conditions; several large, multi-center studies are underway. Policy Lab
Mechanism of Action
Triple Hormone Receptor Activation: GLP-3R simultaneously activates GLP-1, GIP, and glucagon receptors. peptidefiles.com
Appetite Modulation: GLP-1 and GIP receptor activation hehttps://www.peptidefiles.com/retatrutilps reduce appetite and slow gastric emptying in laboratory and animal models. MDPI
Energy Expenditure & Fat Mobilization: Activation of the glucagon receptor component supports increased energy expenditure and fat metabolism. peptidefiles.com
Improved Glucose Homeostasis: Combined incretin effects (GLP-1/GIP) enhance insulin secretion and improve glycemic control in preclinical and early clinical settings. New England Journal of Medicine
References
Triple–Hormone-Receptor Agonist GLP-3R for Obesity — A Phase 2 Trial. New England Journal of Medicine. New England Journal of Medicine
GLP-3R, a GLP-1, GIP and glucagon receptor agonist, for people with type 2 diabetes. The Lancet. The Lancet
GLP-3R: Novel triple receptor agonist for obesity & type 2 diabetes pharmacotherapy. MDPI, Biomolecules (2025). MDPI
TRIUMPH-6 (NCT06859268): Maintenance of weight reduction study. ClinicalTrials.gov. ClinicalTrials.gov
Related products
-
Sale!
-
Glutathione
Price range: $ 39.00 through $ 69.00 Select options This product has multiple variants. The options may be chosen on the product page -
